RecruitingNCT05688176

Barrett's Esophagus and Esophageal Adenocarcinoma, Searching for Reliable Diagnostic RNA Plasma-based Biomarkers

Liquid Biopsies in Esophageal Adenocarcinoma: Barrett's Esophagus and Esophageal Adenocarcinoma, Searching for Reliable Diagnostic RNA Plasma-based Biomarkers

Sponsor

University Hospital, Ghent

Enrollment

100 participants

Start Date

Jun 1, 2016

Study Type

OBSERVATIONAL

Conditions

Esophageal Neoplasms

Summary

This study is designed to perform a explorative search of the transcriptome to detect new circulating diagnostic sensitive and specific biomarkers in patients with Barrett's esophagus or esophageal adenocarcinoma.

Eligibility

Min Age: 18 Years

Inclusion Criteria9

Barrett's Esophagus with length \> 3cm OR esophageal adenocarcinoma histologically proven
Adequate mental faculty, allowing to understand the proposed treatment protocol and provide informed consent
Age over 18 years
No other concurrent malignant disease
No inclusion in other clinical trials interfering with the study protocol
No concurrent chronic systemic immune or hormone therapy, except neoadjuvant chemotherapy
Absence of any severe organ insufficiency
No pregnancy or breast feeding
Written informed consent

Exclusion Criteria8

Pregnancy or breast feeding
Active bacterial, viral or fungal infection
Parenchymal liver disease (any stage cirrhosis)
High risk of bleeding during biopsy (anticoagulants, esophageal varices)
Esophageal squamous cell carcinoma
Helicobacter pylori positive at the time of biopsy sampling
Radiofrequency ablation of the oesophagus
Psychiatric pathology capable of affecting comprehension and judgement faculty

Locations(1)

University hospital Ghent

Ghent, Oost-Vlaanderen, Belgium

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05688176

Related Trials

Proximal Versus Total Gastrectomy for Locally Advanced Siewert Type II-III Gastroesophageal Junction Cancer

NCT074825661 location

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

NCT0644597243 locations

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

NCT0646994443 locations

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

NCT0721379127 locations

Effects of Bright-light Exposure Combined With Specific Exercise Training (BEST) Program in Patients With Cancer

NCT058758702 locations